Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy.

Katz, A

Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy. [electronic resource] - Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy Feb 1993 - 98-109 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

1067-5582

10.1097/00002371-199302000-00004 doi


Animals
Histocompatibility Antigens Class I--analysis
Immunotherapy
Interleukin-6--administration & dosage
Lung Neoplasms--secondary
Melanoma, Experimental--immunology
Mice
Mice, Inbred C57BL
Receptors, Immunologic--analysis
Receptors, Interleukin-6
Recombinant Proteins--administration & dosage
Tumor Cells, Cultured